In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $1.33.
According to TipRanks, Bratzel is a 2-star analyst with an average return of 0.0% and a 42.22% success rate. Bratzel covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Akebia Therapeutics, and Codexis.
Akebia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.00.
The company has a one-year high of $2.48 and a one-year low of $0.65. Currently, Akebia Therapeutics has an average volume of 4.86M.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AKBA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akebia Therapeutics (AKBA) Company Description:
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Read More on AKBA:
